PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 260 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q1 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,350 | -58.0% | 1,000 | -60.0% | 0.00% | – |
| Q2 2023 | $19,887 | +509.7% | 2,500 | +100.0% | 0.00% | – |
| Q1 2023 | $3,262 | +40675.0% | 1,250 | -56.1% | 0.00% | – |
| Q4 2022 | $8 | -99.9% | 2,850 | -9.5% | 0.00% | – |
| Q3 2022 | $9,000 | 0.0% | 3,150 | 0.0% | 0.00% | – |
| Q2 2022 | $9,000 | -52.6% | 3,150 | -50.8% | 0.00% | – |
| Q1 2022 | $19,000 | -69.8% | 6,400 | +103.2% | 0.00% | -100.0% |
| Q4 2021 | $63,000 | -31.5% | 3,150 | -12.5% | 0.00% | -50.0% |
| Q3 2021 | $92,000 | -25.8% | 3,600 | +1.4% | 0.00% | -33.3% |
| Q2 2021 | $124,000 | +21.6% | 3,550 | +16.4% | 0.00% | +50.0% |
| Q1 2021 | $102,000 | -64.3% | 3,050 | -72.3% | 0.00% | -83.3% |
| Q4 2020 | $286,000 | +188.9% | 11,000 | +10.0% | 0.01% | +100.0% |
| Q3 2020 | $99,000 | +482.4% | 10,000 | +100.0% | 0.01% | +500.0% |
| Q2 2020 | $17,000 | -5.6% | 5,000 | -0.7% | 0.00% | -50.0% |
| Q1 2020 | $18,000 | – | 5,037 | +13513.5% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 37 | -84.4% | 0.00% | – |
| Q3 2019 | $1,000 | -99.1% | 237 | -98.4% | 0.00% | -100.0% |
| Q1 2019 | $108,000 | -36.5% | 15,000 | -35.3% | 0.02% | +50.0% |
| Q4 2018 | $170,000 | -23.1% | 23,196 | -43.3% | 0.01% | +11.1% |
| Q3 2018 | $221,000 | +56.7% | 40,889 | +2.6% | 0.01% | +50.0% |
| Q2 2018 | $141,000 | -6.0% | 39,839 | -29.8% | 0.01% | -14.3% |
| Q1 2018 | $150,000 | 0.0% | 56,784 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $150,000 | -50.0% | 56,784 | -0.8% | 0.01% | -41.7% |
| Q3 2017 | $300,000 | +45.6% | 57,234 | -1.0% | 0.01% | +33.3% |
| Q2 2017 | $206,000 | -41.6% | 57,784 | -15.3% | 0.01% | -40.0% |
| Q1 2017 | $353,000 | +8.3% | 68,182 | -20.5% | 0.02% | -6.2% |
| Q4 2016 | $326,000 | -72.5% | 85,742 | -35.3% | 0.02% | -74.2% |
| Q3 2016 | $1,187,000 | +37.2% | 132,547 | +7.8% | 0.06% | +29.2% |
| Q2 2016 | $865,000 | +700.9% | 122,997 | +720.0% | 0.05% | +220.0% |
| Q1 2016 | $108,000 | -85.6% | 15,000 | -73.7% | 0.02% | -70.0% |
| Q4 2015 | $749,000 | – | 57,036 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |